Nuclease Protection ELISA Assay for Diagnosis of Infectious Disease

Opportunity

Available for Licensing

IP Status

US Utility Patent Pending (Not Yet Published)

Inventors

Brian Geiss
Chuck Henry
Jessica Filer

At A Glance

​Researchers at Colorado State University have developed a novel nuclease protection ELISA (NP-ELISA) that has clinical relevance as an alternative to real time RT-PCR.  The assay has excellent specificity with highly similar sequences and is compatible with multiple signal visualization modalities.

Please contact our office for more details.

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  19-067

Background

​Many viral diseases including Zika virus, influenza, dengue virus, and chikungunya virus present with general, nonspecific symptoms that encumber differential diagnosis.  Thus, the Center for Disease Control (CDC) typically recommends NAT on serum, urine, or other biologically-relevant samples to diagnose viral disease during the early state of infection – typically done with approved real-time polymerase chain reaction (PCR) assays.

Early and accurate diagnosis is crucial to monitor infection outcomes and provide timely interventions.  However, gold standard PCR assays are labor-intensive and require expensive reagents and instrumentation. Nuclease protection has been used for decades to detect and quantify nucleic acid but has not yet been investigated as a diagnostic tool for infectious disease.

Technology Overview

Researchers at Colorado State University have developed a nuclease protection-ELISA (NP-ELISA) for the specific and sensitive detection of nucleic acid. In contrast to the nuclease protection sandwich hybridization assay (NPA-SH), the NP-ELISA uses a single oligo capture probe.

Figure 1. (below) Demonstrates a probe designed to have specificity towards a respective Zika (ZIKV) or Kunjin (KUNV) virus sequence.  The capture probe is mixed with a nucleic acid target (i) and hybridized products (ii) are  immobilized  to  the bottom of a microtiter plate and are subjected to a digestion reaction with S1 nuclease which degrades single stranded nucleic acid including unbound probe (iii). HRP-conjugated anti-Digoxigenin antibody binds to a digoxigenin molecule bound to the 3’ end of the capture probe and facilitates an enzymatic readout (iv).

The assay was validated using synthesized target oligos and then compared for colorimetric, chemiluminescent, and electrochemical detection methods.  The NP-ELISA is a new valuable approach for NAT that uses fewer reagents and inexpensive instrumentation compared to real-time PCR.

Benefits
  • Excellent specificity
  • Colorimetric and Electrochemical Detection of Nucleic Acid
  • Relevant clinical range for nucleic acid detection
  • Significantly less expensive and more portable (accessible use in remote areas)
  • Potential as direct, multiplexed, and hand-held detection of pathogens
  • NP-ELISA is a viable alternative for clinical NAT
Applications
  • Clinical diagnostic for infectious disease
  • Potential for point-of-care applications
Publications

Filer, Jessica E., et al. “A Nuclease Protection ELISA Assay for Colorimetric and Electrochemical Detection of Nucleic Acids.” Analytical Methods, The Royal Society of Chemistry, 24 Jan. 2019, pubs.rsc.org/en/content/articlelanding/2019/ay/c8ay02729c.

Last updated: August 2020

Add keywords or various names of inventors here (text is hidden)